The drug development process is a long journey, beginning with drug discovery, moving through nonclinical and clinical studies, and ultimately culminating in regulatory approval. With many steps in between, each as important as the next, multiple factors regarding development strategy and approach must be considered at the earliest stages. This blog post offers advice for…
Expertise: Consulting 44 results
One of the most common formulation issues that sponsors of new drug or biologic products face is the qualification of novel excipients. Although novel excipients can be a part of any new drug application (NDA) or biologics license application (BLA) development program, they seem to be more common with the 505(b)(2) pathway, since many companies…
Before the 2012 Food and Drug Administration (FDA) Nonprescription Safe Use Regulatory Expansion (NSURE) initiative, sponsors were transitioning prescription drugs (Rx) to over-the-counter (OTC). Streamlined access to effective treatments clearly benefits patients and payers. At the same time, easier access for consumers typically results in increased sales and profitability for pharma and biotech companies. As…
Morrisville, N.C., February 22, 2022 — Premier Research launched Premier Consulting today by consolidating two legacy brands within its portfolio — Regulatory Professionals, Inc. (RPI) and Camargo Pharmaceutical Services. Premier Consulting is a unified strategic product development and global regulatory consulting brand positioned for market leadership in support of emerging biotech and specialty pharma companies. The new…
Morrisville, N.C., May 18, 2021 — Premier Research announced today that it has acquired Camargo Pharmaceutical Services based in Cincinnati. Premier Research is a leading provider of strategic and regulatory advisory services as well as clinical development services to the biotechnology, specialty pharma, and medical device industry. Camargo is a leading global strategy, regulatory, and…
Traditionally, Phase 1 trials commonly utilize 3+3 designs to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D). Studies have shown, however, that two out of three trials employing a 3+3 design failed in identifying the MTD, and better approaches are needed.1 During Premier Research’s recent webinar Alternative Designs to the…
Developing a new biopharmaceutical product is a lengthy, high-stakes journey. It takes, on average, at least 10 years and over $2 billion to successfully bring a new drug to market, and only 10% to 15% of products ultimately receive regulatory approval.[1] A comprehensive plan and the right regulatory and therapeutic expertise can significantly accelerate the…
DURHAM, N.C., February 1, 2021 — Premier Research, the clinical research company that delivers outcome-focused insights which support sponsors in developing life-changing therapies, announced today that Abie Ekangaki, Ph.D., Vice President, Statistical Consulting, has been recognized by the American Statistical Association (AMSTAT) in celebration of Black History Month. Dr. Ekangaki is one of ten Black…
Drug development is a resource-intensive endeavor. Seeking input from the U.S. Food and Drug Administration throughout the journey can help optimize those resources and maximize the likelihood of regulatory approval. When preparing to submit a new drug application (NDA), a pre-NDA meeting with the FDA can be a critical step in ensuring the submission of…
The Electronic Common Technical Document (eCTD) is the standard format for submitting applications, amendments, supplements, and reports to the U.S. Food & Drug Administration (FDA). The eCTD harmonizes the regulatory review process for global drug development, as its structure is based on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use…